OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma
OncXerna Therapeutics Announces Final Results and New Xerna™ TME Panel Biomarker Data from a Phase 2 Trial of Bavituximab Plus Pembrolizumab in Patients with Previously Untreated Advanced Hepatocellular Carcinoma - read this article along with other careers information, tips and advice on BioSpace
United States University Of Texas Hagop Youssoufian Ashleyr Robinson David Hsieh Adjunct Professor Of Medicine At Brown University
Source: biospace.com